Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

The formation of fibrils can also result in products with lower strengths than expected or indicated on the label, it says. Novo Nordisk made ... sold as Mounjaro for diabetes and Zepbound for ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

A bill to lower the price of insulin drugs and supplies for more North Dakotans attracted passionate discussion at a Thursday ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Trump has pledged to implement "very high" tariffs on Denmark if it does not sell Greenland to the United States, also noting ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

President-elect Donald Trump 's threat to "tariff Denmark at a very high level" if it refuses to give up Greenland could ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

Browse in-depth TOC on " Global Biotechnology industry Outlook " 10 - Tables 20 - Figures 70 - Pages . The Global Biotech ...